Perinatal Mental Health and Substance Use Disorders

Kate Austman, MD, FASAM
Addiction Medicine/FP/OB
Gibson Recovery Optimizing Wellness

Epidemiol ogy in the US

- Cystic Fibrosis: 0.03% (1 in 3200 live births in US)
- Gestational Diabetes: 7%
- Pre-eclampsia: 4%
- Anemia: 5%
- Illicit drug use: 5%

Epidemiol ogy cont.


Perinatal mental health conditions

Affect more than 1 in 5 perinatal individuals

One of the most common complications of pregnancy and the year after childbirth

ACOG Clinical Practice Guideline June 202

Perinatal Mental Health



ACOG Clinical Practice Bulletin June 2023

Risk Factors Associate d with Perinatal Mental Health Condition

Biological

- ·Personal mental health history
- •Family mental health history
 - Genetic predisposition
 - ·Physical health
- •Hormonal, immunologic, neurobiologic triggers or changes
 - •Insomnia & sleep disturbances
 - Substance use disorder

Environmental

- Adverse childhood experiences
 - Intimate partner violence
 - Abuse history
- · Adverse or stressful life events
 - Cultural expectations
 - Pregnancy loss
- . Obstetric and medical complications
 - •Traumatic birth experience
 - Neonatal complications/NICU admission
 - . Difficulty breastfeeding
 - Dysregulated infant†

Psychosocial


- Race/ethnicity as social construct & experience of racism
 - Age (adolescent, > 40 years)
- Military (active-duty, veteran, or veteran-dependent)
- Socioeconomic situation & unemployment
 - Education level
- •Inadequate social supports
- •Relationship quality & isolation
 - Pregnancy intendedness
- •Self-esteem & temperament
 - Coping & social skills
 - Frequent rumination

Where can I find SBIRT?

Screening


Brief Intervention

Referral to Treatment




https://sites.education.miami.edu/sbirt/w

Mental Health Screening




Recommedations

- USPSTF: screen every pregnant person for depression with EPDS or PHQ-9; if positive screen for BPD with Mood Disorder Questionnaire
- ACOG: screen with EPDS or PHQ-9
- AAFP: screen with EPDS or PHQ-9
- AAP: screen with EPDS or PHQ-9



*If all screens are negative, tell the patient that they were negative and say, "if something changes, please let us know. We are here."





Perinatal Antidepressant Algorithm

This information is produced by the University of Illinois at Chicago (UIC) by Illinois DocAssist as a summary of research on antidepressants in human pregnancy



866-986-2778





TR = Treatment range

^{© 2023} The Board of Trustees of the University of Illinois. All rights reserved. Originally created by the Illinois Perinatal Mental Health Project; revised in 2023 by Ashley Mulvihill, MD, Angela Shrestha, MD and Illinois DocAssist

Perinatal
Substance Use
Disorders





• According to the October 2023 Illinois Maternal Morbidity and Mortality Review Report, substance use disorders are the leading cause of pregnancy associated deaths in Illinois

- Deaths reviewed: 263
- 2018-2020



How to screen

- ACOG and ASAM, along with other major medical associations recommend that all women should be screened using a validated screening test, and not biomechanical measures
- Normalize screening
- Ask every patient

Screening Tools Validated in Pregnancy

- T-ACE
- TWEAK
- 4 P's (5 P's)
- Substance Use Profile-Pregnancy
- AUDIT-C

Screening Tools Not Validated in Pregnancy but Still Often used Screening and Assessment Tools Chart

- CAGE
- NIDA
- TAPS

Screening tools

Tool	Substance type		Patient age		How tool is administered	
	Alcohol	Drugs	Adults	Adolescents	Self- administered	Clinician- administered
Screening to Brief Intervention (S2BI)	Х	Х		х	Х	Х
Brief Screener for Alcohol, Tobacco, and other Drugs (BSTAD)	Х	Х		Х	Х	X
Tobacco, Alcohol, Prescription medication, and other Substance use (TAPS)	Х	Х	Х		Х	X
Alcohol Screening and Brief Intervention for Youth: A Practitioner's Guide (NIAAA)	Х			х		Х
Opioid Risk Tool – OUD (ORT- OUD) Chart		Х	Х		Х	

Tool	Substance type		Patient age		How tool is administered	
	Alcohol	Drugs	Adults	Adolescents	Self- administered	Clinician- administered
Tobacco, Alcohol, Prescription medication, and other Substance use (TAPS)	Х	Х	Х		Х	X
CRAFFT ☑	×	Х		Х	Х	Х
Drug Abuse Screen Test (DAST- 10)* For use of this tool - please contact Dr. Harvey Skinner □		х	х		X	х
Drug Abuse Screen Test (DAST-20: Adolescent version)* For use of this tool - please contact Dr. Harvey Skinner □		х		Х	X	Х
NIDA Drug Use Screening Tool (NMASSIST) (discontinued in favor of TAPS screening above)	Х	х	X			X
Alcohol Screening and Brief Intervention for Youth: A Practitioner's Guide (NIAAA)	х			Х		Х

UDS is only a moment in time, it does not determine use disorder

False positives

- +Fentanyl following epidural
- +amphetamine in the context of prescribed bupropion
- +amphetamine in the context of labetalol

False negatives

• Do you know if your hospital has POC fentanyl testing?

Why is the test being ordered?





(biochemical) testing should only be ordered for clinical purposes and to guide quality medical care Often tests are ordered for reasons that are not clinically actionable, but ordered for punitive purposes

The benefit of protocols

Can reduce inequality

Makes decision making for team members simpler

Support of birthing patient

Support of infant

Legal Issues


- APORS form → IDPH
- Positive toxicology of non-prescribed substance \rightarrow DCFS
- Different responses in different regions
- Illinois does not have laws that outline which infants should receive testing
- Supreme court: must have informed consent or a valid warrant in order to do UDS on pregnant patient (Gottlieb, 2001)

Why would someone who uses drugs want to be pregnant?

Don't they
know they
are harming
the baby?

Illinois Perinatal Quality Collaborative





Opioid Use Disorder



Medicatio ns for Opioid Use Disorder

Methadone

Buprenorphine

- Suboxone
- Subutex
- Sublocade
- Brixadi

Naltrexone

"Comfort" meds

Tobacco Use Disorder

Offer treatment: varenicline, bupropion, NRT

There is benefit in reducing use

Newborn withdrawal from nicotine can look similar to early opioid withdrawal

Difference is that nicotine withdrawal occurs earlier

Cannabis

Just because it's legal, doesn't make it safe

Harmful effects to newborn

May worsen hyperemesis

May worsen anxiety

N-acetylcysteine - safe in pregnancy

Alcohol Use Disorder No safe amount has been established

Leading cause of preventable birth defects
Value in brief intervention and education by health care provider

Stimulants

Cocaine

Methamphetamine

Adderall, Ritalin, etc

CBT

Difficult to treat due to acute and chronic withdrawal symptoms

Adulteration of supply

Neonatal withdrawal symptoms

Newborns are not born addicted to a substance

requires
cravings, loss
of control,
compulsions and
adverse

Be thoughtful about documentation

?Finnegan scoring

Eat, Sleep, Console

For longer acting opioids (methadone, fentanyl) monitor baby for 4-7 days

Benefits of Breastfeeding in Substance Exposed Dyads

- Same benefits for breastfeeding as in general population
- Breastfeeding known to reduce the severity of NOWS
 - Decreased pharmacologic treatment
 - Decreased length of stay for infant
- Help mothers bond with their infant, which can reduce stress and support their recover

Concerns about breastfeeding in individuals actively using non-prescribed substances

Reduced parental response to infant feeding cues

Infant substance exposure through breast milk

Reduced breastfeeding ability

Potential alterations in neonatal brain development

Timing of breastfeeding initiation

- 2015 ABM guidelines \rightarrow wait 30-90 days from last use
- 2023 ABM guidelines \rightarrow it's more and less complicated!
 - Predictive value of continued use post-partum based on 3rd trimester UDT: 36%
 - UDT at delivery has strongest association with ongoing substance use postpartum
 - Most substances eliminated in hours to days (not days to weeks)
 - Women who discontinue use by or during delivery should be supported in breastfeeding

 Rooming-in and skin-to-skin positioning should be encouraged regardless of breastfeeding status







Customers Providers About News Contact

IDHS > About IDHS > Divisions > Substance Use Prevention & Recovery > SUPR Opioid Resources >

IDHS/SUPR Drug Overdose Prevention Program

About the Drug Overdose Prevention Program (DOPP)

Naloxone is a safe and effective opioid overdose reversal medication that **saves lives**. The Illinois Department of Human Services, Division of Substance Use Prevention and Recovery (IDHS/SUPR) aims to reduce the number of opioid overdoses through the expansion of community-based Overdose Education and Naloxone Distribution (OEND) services. IDHS/SUPR manages the Drug Overdose Prevention Program (DOPP), as legislated in the Substance Use Disorder Act, which allows organizations to order free Narcan (a form of naloxone) through our Access Narcan program to distribute within their communities. These programs are essential to ending the overdose crisis in Illinois by making sure that anybody who may witness an opioid overdose is equipped with naloxone and the knowledge they need to save a life.

All organizations (except pharmacies) that use the <u>Illinois Department of Public Health Naloxone Standing Order</u> must enroll in DOPP. IDHS/SUPR encourages all other organizations to enroll even if they conduct OEND services under their own standing order.

What if I'm looking for naloxone or fentanyl/xylazine testing strips without enrolling in DOPP?

If you are seeking no-cost naloxone for your first-aid kits or fentanyl/xylazine testing strips, there are funded OEND service organizations responsible for all counties who can provide these resources. OENDs can also provide larger quantities if the interested organization decides that they do not want to enroll in DOPP.

- To find the program designated by IDHS/SUPR to serve your county: <u>Illinois Overdose Education and Naloxone Distribution (OEND) Programs funded by IPDO and SOR grants, by County.</u>
- To find a Drug Overdose Prevention Program provider near you, visit the Illinois Helpline.

Who can register to be part of DOPP?

References

- Howard, L.M. and Khalifeh, H. (2020), Perinatal mental health: a review of progress and challenges. World Psychiatry, 19: 313-327. https://doi.org/10.1002/wps.20769
- https://nida.nih.gov/nidamed-medical-health-professionals/screening-tools-resources/chart-screening-tools
- Screening and Diagnosis of Mental Health Conditions During Pregnancy and Postpartum: ACOG Clinical Practice Guideline No. 4. Obstet Gynecol. 2023 Jun 1;141(6):1232-1261. doi: 10.1097/AOG.000000000005200. PMID: 37486660.
- Treatment and Management of Mental Health Conditions During Pregnancy and Postpartum: ACOG Clinical Practice Guideline No. 5 Obstet Gynecol. 2023;141(6):1262-1288. doi:10.1097/AOG.00000000005202.
- Jordan J. Hoerr, Anthony M. Heard, Meredith M. Baker, Joshua Fogel, Anne Elizabeth Glassgow, William C. Kling, Maureen D. Clark, James P. Ronayne,
- Substance-exposed newborn infants and public health law: Differences in addressing the legal mandate to report, Child Abuse & Neglect, Volume 81, 2018, Pages 206-213, ISSN 0145-2134, https://doi.org/10.1016/j.chiabu.2018.04.021.
- Byatt N, Masters GA, Bergman AL, Moore Simas TA. Screening for Mental Health and Substance Use
 Disorders in Obstetric Settings. Curr Psychiatry Rep. 2020 Sep 16;22(11):62. doi: 10.1007/s11920-020-01182z. PMID: 32936340.

References

- Holland J, Brown R. Neonatal venlafaxine discontinuation syndrome: A mini-review. Eur J Paediatr Neurol. 2017 Mar;21(2):264-268. doi: 10.1016/j.ejpn.2016.11.003. Epub 2016 Nov 25. PMID: 27931774.
- Yang A, Ciolino JD, Pinheiro E, Rasmussen-Torvik LJ, Sit DKY, Wisner KL. Neonatal Discontinuation Syndrome in Serotonergic Antidepressant-Exposed Neonates. J Clin Psychiatry. 2017 May;78(5):605-611. doi: 10.4088/JCP.16m11044. PMID: 28570796; PMCID: PMC7087396.
- Warburton W, Hertzman C, Oberlander TF. A register study of the impact of stopping third trimester selective serotonin reuptake inhibitor exposure on neonatal health. Acta Psychiatr Sca10.1111/j.1600-0447.2009.01490.x. Epub 2009 Oct 30. PMID: 19878137nd. 2010 Jun;121(6):471-9. doi:.
- Harris M, Schiff DM, Saia K, Muftu S, Standish KR, Wachman EM. Academy of Breastfeeding Medicine Clinical Protocol #21: Breastfeeding in the Setting of Substance Use and Substance Use Disorder (Revised 2023).
 Breastfeed Med. 2023 Oct;18(10):715-733. doi: 10.1089/bfm.2023.29256.abm. PMID: 37856658; PMCID: PMC10775244.
- Campbell ND. When Should Screening and Surveillance Be Used during Pregnancy? AMA J Ethics. 2018 Mar 1;20(1):288-295. doi: 10.1001/journalofethics.2018.20.3.msoc1-1803. PMID: 29542439.

References

- Stritzel, H. (2023). Substance Use-Associated Infant Maltreatment Report Rates in the Context of Complex Prenatal Substance Use Policy Environments. Child Maltreatment, 0(0). https://doi.org/10.1177/10775595231213404
- Gottlieb S. Pregnant women cannot be tested for drugs without consent. BMJ. 2001 Mar 31;322(7289):753.
 PMID: 11282855; PMCID: PMC1119949.
- Chin JM, Chen E, Wright T, Bravo RM, Nakashima E, Kiyokawa M, Karasaki K, Estrada P, Ghatnekar R, Lee MJ, Bartholomew ML. Urine drug screening on labor and delivery. Am J Obstet Gynecol MFM. 2022 Nov;4(6):100733. doi: 10.1016/j.ajogmf.2022.100733. Epub 2022 Aug 26. PMID: 36038068.
- Peterson JA, Koelper NC, Curley C, Sonalkar SR, James AT. Reduction of racial disparities in urine drug testing after implementation of a standardized testing policy for pregnant patients. Am J Obstet Gynecol MFM. 2023 May;5(5):100913. doi: 10.1016/j.ajogmf.2023.100913. Epub 2023 Mar 3. PMID: 36870533.